FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377010670> ?p ?o ?g. }

• W4377010670 abstract "Abstract Background Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor (e.g., palbociclib, ribociclib, abemaciclib) to endocrine therapy substantially prolongs progression-free survival and in the case of a CDK 4/6i also overall survival. However, the prerequisite is adherence to therapy over the entire course of treatment. However, particularly with new oral drugs, adherence presents a challenge to disease management. In this context, factors influencing adherence include maintaining patients’ satisfaction and early detection/management of side effects. New strategies for continuous support of oncological patients are needed. An eHealth-based platform can help to support therapy management and physician–patient interaction. Methods PreCycle is a multicenter, randomized, phase IV trial in HR + HER2 − MBC. All patients ( n = 960) receive the CDK 4/6 inhibitor palbociclib either in first (62.5%) or later line (37.5%) together with endocrine therapy (AI, fulvestrant) according to national guidelines. PreCycle evaluates and compares the time to deterioration (TTD) of QoL in patients supported by eHealth systems with substantially different functionality: CANKADO active vs. inform. CANKADO active is the fully functional CANKADO-based eHealth treatment support system. CANKADO inform is a CANKADO-based eHealth service with a personal login, documentation of daily drug intake, but no further functions. To evaluate QoL, the FACT-B questionnaire is completed at every visit. As little is known about relationships between behavior (e.g., adherence), genetic background, and drug efficacy, the trial includes both patient-reported outcome and biomarker screening for discovery of forecast models for adherence, symptoms, QoL, progression free survival (PFS), and overall survival (OS). Discussion The primary objective of PreCycle is to test the hypothesis of superiority for time to deterioration (TTD) in terms of DQoL = “Deterioration of quality of life” (FACT-G scale) in patients supported by an eHealth therapy management system (CANKADO active) versus in patients merely receiving eHealth-based information (CANKADO inform). EudraCT Number: 2016–004191-22" @default.
• W4377010670 created "2023-05-19" @default.
• W4377010670 creator A5001617286 @default.
• W4377010670 creator A5006268438 @default.
• W4377010670 creator A5017728105 @default.
• W4377010670 creator A5020142852 @default.
• W4377010670 creator A5021290996 @default.
• W4377010670 creator A5022444628 @default.
• W4377010670 creator A5024023144 @default.
• W4377010670 creator A5025408460 @default.
• W4377010670 creator A5027231412 @default.
• W4377010670 creator A5029656956 @default.
• W4377010670 creator A5031666050 @default.
• W4377010670 creator A5032626301 @default.
• W4377010670 creator A5032928558 @default.
• W4377010670 creator A5034764832 @default.
• W4377010670 creator A5035775338 @default.
• W4377010670 creator A5059885667 @default.
• W4377010670 creator A5069170386 @default.
• W4377010670 creator A5070905598 @default.
• W4377010670 creator A5072762948 @default.
• W4377010670 creator A5074391693 @default.
• W4377010670 creator A5081765599 @default.
• W4377010670 creator A5088637879 @default.
• W4377010670 date "2023-05-17" @default.
• W4377010670 modified "2023-09-30" @default.
• W4377010670 title "PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant" @default.
• W4377010670 cites W1464936406 @default.
• W4377010670 cites W1525997899 @default.
• W4377010670 cites W1538699542 @default.
• W4377010670 cites W1649504389 @default.
• W4377010670 cites W1848284152 @default.
• W4377010670 cites W1857624176 @default.
• W4377010670 cites W1979608435 @default.
• W4377010670 cites W2003142639 @default.
• W4377010670 cites W2014665762 @default.
• W4377010670 cites W2047101195 @default.
• W4377010670 cites W2074780401 @default.
• W4377010670 cites W2088943607 @default.
• W4377010670 cites W2094101973 @default.
• W4377010670 cites W2094232837 @default.
• W4377010670 cites W2144790402 @default.
• W4377010670 cites W2160289137 @default.
• W4377010670 cites W2552099557 @default.
• W4377010670 cites W2620925856 @default.
• W4377010670 cites W4211005384 @default.
• W4377010670 doi "https://doi.org/10.1186/s13063-023-07306-z" @default.
• W4377010670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37198674" @default.
• W4377010670 hasPublicationYear "2023" @default.
• W4377010670 type Work @default.
• W4377010670 citedByCount "0" @default.
• W4377010670 crossrefType "journal-article" @default.
• W4377010670 hasAuthorship W4377010670A5001617286 @default.
• W4377010670 hasAuthorship W4377010670A5006268438 @default.
• W4377010670 hasAuthorship W4377010670A5017728105 @default.
• W4377010670 hasAuthorship W4377010670A5020142852 @default.
• W4377010670 hasAuthorship W4377010670A5021290996 @default.
• W4377010670 hasAuthorship W4377010670A5022444628 @default.
• W4377010670 hasAuthorship W4377010670A5024023144 @default.
• W4377010670 hasAuthorship W4377010670A5025408460 @default.
• W4377010670 hasAuthorship W4377010670A5027231412 @default.
• W4377010670 hasAuthorship W4377010670A5029656956 @default.
• W4377010670 hasAuthorship W4377010670A5031666050 @default.
• W4377010670 hasAuthorship W4377010670A5032626301 @default.
• W4377010670 hasAuthorship W4377010670A5032928558 @default.
• W4377010670 hasAuthorship W4377010670A5034764832 @default.
• W4377010670 hasAuthorship W4377010670A5035775338 @default.
• W4377010670 hasAuthorship W4377010670A5059885667 @default.
• W4377010670 hasAuthorship W4377010670A5069170386 @default.
• W4377010670 hasAuthorship W4377010670A5070905598 @default.
• W4377010670 hasAuthorship W4377010670A5072762948 @default.
• W4377010670 hasAuthorship W4377010670A5074391693 @default.
• W4377010670 hasAuthorship W4377010670A5081765599 @default.
• W4377010670 hasAuthorship W4377010670A5088637879 @default.
• W4377010670 hasBestOaLocation W43770106701 @default.
• W4377010670 hasConcept C121608353 @default.
• W4377010670 hasConcept C126322002 @default.
• W4377010670 hasConcept C143998085 @default.
• W4377010670 hasConcept C151730666 @default.
• W4377010670 hasConcept C159110408 @default.
• W4377010670 hasConcept C160735492 @default.
• W4377010670 hasConcept C162324750 @default.
• W4377010670 hasConcept C168563851 @default.
• W4377010670 hasConcept C202645933 @default.
• W4377010670 hasConcept C2775930923 @default.
• W4377010670 hasConcept C2779343474 @default.
• W4377010670 hasConcept C2779744173 @default.
• W4377010670 hasConcept C2779951463 @default.
• W4377010670 hasConcept C2780482068 @default.
• W4377010670 hasConcept C50522688 @default.
• W4377010670 hasConcept C530470458 @default.
• W4377010670 hasConcept C71924100 @default.
• W4377010670 hasConcept C84606932 @default.
• W4377010670 hasConcept C86803240 @default.
• W4377010670 hasConceptScore W4377010670C121608353 @default.
• W4377010670 hasConceptScore W4377010670C126322002 @default.
• W4377010670 hasConceptScore W4377010670C143998085 @default.
• W4377010670 hasConceptScore W4377010670C151730666 @default.
• W4377010670 hasConceptScore W4377010670C159110408 @default.
• W4377010670 hasConceptScore W4377010670C160735492 @default.

• next